What is Athersys Inc?
Athersys Inc is a biotechnology enterprise dedicated to the discovery and development of therapeutic candidates aimed at extending and enhancing human life. At the core of its operations is the MultiStem cell therapy, a patented, adult-derived regenerative medicine product designed for broad clinical application. By leveraging a robust network of strategic partnerships and collaborations, Athersys is actively advancing its product candidates through rigorous clinical trials. The company occupies a critical position in the life sciences landscape, focusing on high-unmet-need areas such as critical care and immune-mediated diseases, where its off-the-shelf technology offers a scalable alternative to traditional therapeutic interventions.
How much funding has Athersys Inc raised?
Athersys Inc has raised a total of $264.5M across 9 funding rounds:
Share Placement
$9M
Debt
$25M
Stock Offering
$23M
Debt
$100M
Share Placement
$7M
Share Placement
$12M
Other Financing Round
$10.4M
Share Placement (2012): $9M supported by Undisclosed
Debt (2013): $25M featuring Aspire Capital
Stock Issuance/Offering (2017): $23M backed by Undisclosed
Debt (2018): $100M with participation from Aspire Capital
Share Placement (2020): $7M led by Healios
Share Placement (2022): $12M, investors not publicly disclosed
Other Financing Round (2023): $10.4M, investors not publicly disclosed
Key Investors in Athersys Inc
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
Pappas Ventures
Pappas Capital is a leading healthcare venture capital firm that specializes in advancing biopharma, biotech, and medical technologies aimed at improving patient outcomes.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
What's next for Athersys Inc?
Looking ahead, Athersys Inc is positioned to leverage its recent capital influx to accelerate the commercialization trajectory of its MultiStem platform. The company's strategic roadmap emphasizes the completion of ongoing clinical trials and the strengthening of its collaborative network to facilitate global market entry. As the firm transitions from a research-heavy entity to a more commercially oriented organization, the focus remains on achieving regulatory milestones and demonstrating the clinical efficacy of its regenerative solutions. Investors and stakeholders are closely monitoring the company's ability to translate its scientific advancements into tangible patient outcomes, which will be pivotal for its long-term growth and market valuation in the competitive biotechnology sector.
See full Athersys Inc company page
